INTRODUCTION: P-glycoprotein (P-gp), an efflux transporter, is a significant barrier to drug entry into the brain and the fetus. The positron emission tomography (PET) ligand, [(11)C]-verapamil, has been used to measure in vivo P-gp activity at various tissue-blood barriers of humans and animals. Since verapamil is extensively metabolized in vivo, it is important to quantify the extent of verapamil metabolism in order to interpret such P-gp activity. Therefore, we developed a rapid solid-phase extraction (SPE) method to separate, and then quantify, verapamil and its radiolabeled metabolites in plasma. METHODS: Using high-performance liquid chromatography (HPLC), we established that the major identifiable circulating radioactive metabolite of [(11)C]-verapamil in plasma of humans and the nonhuman primate, Macaca nemestrina, was [(11)C]-D-617/717. Using sequential and differential pH elution on C(8) SPE cartridges, we developed a rapid method to separate [(11)C]-verapamil and [(11)C]-D-617/717. Recovery was measured by spiking the samples with the corresponding nonradioactive compounds and assaying these compounds by HPLC. RESULTS: Verapamil and D-617/717 recovery with the SPE method was >85%. When the method was applied to PET studies in humans and nonhuman primates, significant plasma concentration of D-617/717 and unknown polar metabolite(s) were observed. The SPE and the HPLC methods were not significantly different in the quantification of verapamil and D-617/717. CONCLUSIONS: The SPE method simultaneously processes multiple samples in less than 5 min. Given the short half-life of [(11)C], this method provides a valuable tool to rapidly determine the concentration of [(11)C]-verapamil and its [(11)C]-metabolites in human and nonhuman primate plasma.
INTRODUCTION: P-glycoprotein (P-gp), an efflux transporter, is a significant barrier to drug entry into the brain and the fetus. The positron emission tomography (PET) ligand, [(11)C]-verapamil, has been used to measure in vivo P-gp activity at various tissue-blood barriers of humans and animals. Since verapamil is extensively metabolized in vivo, it is important to quantify the extent of verapamil metabolism in order to interpret such P-gp activity. Therefore, we developed a rapid solid-phase extraction (SPE) method to separate, and then quantify, verapamil and its radiolabeled metabolites in plasma. METHODS: Using high-performance liquid chromatography (HPLC), we established that the major identifiable circulating radioactive metabolite of [(11)C]-verapamil in plasma of humans and the nonhuman primate, Macaca nemestrina, was [(11)C]-D-617/717. Using sequential and differential pH elution on C(8) SPE cartridges, we developed a rapid method to separate [(11)C]-verapamil and [(11)C]-D-617/717. Recovery was measured by spiking the samples with the corresponding nonradioactive compounds and assaying these compounds by HPLC. RESULTS: Verapamil and D-617/717 recovery with the SPE method was >85%. When the method was applied to PET studies in humans and nonhuman primates, significant plasma concentration of D-617/717 and unknown polar metabolite(s) were observed. The SPE and the HPLC methods were not significantly different in the quantification of verapamil and D-617/717. CONCLUSIONS: The SPE method simultaneously processes multiple samples in less than 5 min. Given the short half-life of [(11)C], this method provides a valuable tool to rapidly determine the concentration of [(11)C]-verapamil and its [(11)C]-metabolites in human and nonhuman primate plasma.
Authors: Mark Lubberink; Gert Luurtsema; Bart N M van Berckel; Ronald Boellaard; Rolf Toornvliet; Albert D Windhorst; Eric J F Franssen; Adriaan A Lammertsma Journal: J Cereb Blood Flow Metab Date: 2006-06-07 Impact factor: 6.200
Authors: Peng Hsiao; Lucy Sasongko; Jeanne M Link; David A Mankoff; Mark Muzi; Ann C Collier; Jashvant D Unadkat Journal: J Pharmacol Exp Ther Date: 2006-01-13 Impact factor: 4.030
Authors: Gert Luurtsema; Carla F M Molthoff; Robert C Schuit; Albert D Windhorst; Adriaan A Lammertsma; Eric J F Franssen Journal: Nucl Med Biol Date: 2005-01 Impact factor: 2.408
Authors: A H Schinkel; J J Smit; O van Tellingen; J H Beijnen; E Wagenaar; L van Deemter; C A Mol; M A van der Valk; E C Robanus-Maandag; H P te Riele Journal: Cell Date: 1994-05-20 Impact factor: 41.582
Authors: Francisco S Chung; Jayson S Santiago; Miguel Francisco M De Jesus; Camille V Trinidad; Melvin Floyd E See Journal: Am J Cancer Res Date: 2016-08-01 Impact factor: 6.166
Authors: Li Liu; Ann C Collier; Jeanne M Link; Karen B Domino; David A Mankoff; Janet F Eary; Charles F Spiekerman; Peng Hsiao; Anand K Deo; Jashvant D Unadkat Journal: Drug Metab Dispos Date: 2015-09-09 Impact factor: 3.922
Authors: Alice Ban Ke; Sara Eyal; Francisco S Chung; Jeanne M Link; David A Mankoff; Mark Muzi; Jashvant D Unadkat Journal: J Nucl Med Date: 2013-01-28 Impact factor: 10.057
Authors: Sara Eyal; Francisco S Chung; Mark Muzi; Jeanne M Link; David A Mankoff; Amal Kaddoumi; Finbarr O'Sullivan; Mary F Hebert; Jashvant D Unadkat Journal: J Nucl Med Date: 2009-05 Impact factor: 11.082
Authors: F S Chung; S Eyal; M Muzi; J M Link; D A Mankoff; A Kaddoumi; F O'Sullivan; P Hsiao; J D Unadkat Journal: Br J Pharmacol Date: 2009-12-04 Impact factor: 9.473